article
Beyond the hype: a veteran’s honest assessment of AI in drug discovery – Part 2
Thibault Géoui explains why AI could finally help pharma overcome its productivity crisis and why the payoff won’t come as quickly as the optimists claim.
List view / Grid view
Therapeutics
news
New therapy targets triglycerides to prevent aneurysms
A new study shows high triglyceride levels directly cause abdominal aortic aneurysms – highlighting triglyceride-lowering therapies as a potential new treatment.
news
From graphene to grey matter: tech that supercharges brain organoids
Researchers at UC San Diego have discovered a graphene-based technology that accelerates the maturation of human brain organoids, offering a safer, non-invasive way to model diseases like Alzheimer’s.
news
Kidney organoids reveal hidden toxicities in AAV gene therapy
Stem cell-derived kidney organoids have revealed hidden toxicities in adeno-associated virus (AAV) gene therapy delivery – offering a powerful new way to improve the safety of future treatments.
news
Striosomes may hold the key to better treatments for mental disorders
Scientists have developed a new computational model that reveals how the striosomal compartment of the brain’s striatum influences decision-making – which could lead to improved therapies for psychiatric disorders.
news
Researchers identify early intervention target for cerebral palsy dystonia
Researchers have developed an easy-to-use method for measuring leg dystonia in children with cerebral palsy – allowing doctors to personalise treatments more effectively.
article
What if drug discovery took months, not decades?
Drug discovery is slow, costly and often unsuccessful. DTR hears how GATC Health is applying AI and multiomics to make the process faster, more precise and less reliant on trial and error.
news
New CRISPR breakthrough could transform sickle cell treatment
Researchers at UNSW Sydney have unveiled a next-generation CRISPR tool that could lead to safer treatments for genetic disorders, including Sickle Cell.
article
How to select the optimal bispecific antibody format for therapeutic success
Choosing the right bispecific antibody format can make or break your therapy’s success. This article explores how format impacts function, manufacturability and development strategy - helping you make the best choice from the start.
news
How to select the optimal bispecific antibody format for therapeutic success
Discover the key scientific, strategic and manufacturing factors that could decide whether your bsAb succeeds in the clinic or stalls in development.
article
Challenges in developing robust potency assays for ADCs
Developing robust potency assays for Antibody-Drug Conjugates (ADCs) is crucial for ensuring their clinical success, but designing assays that meet both technical and regulatory standards is challenging. Here, Abzena’s CSO Campbell Bunce explores the complexities of assay development and the importance of ensuring accuracy, consistency and regulatory alignment for ADCs…
news
FDA-approved asthma drug may protect against food allergy reactions
An existing asthma drug has been shown to almost completely prevent life-threatening allergic reactions to food in mice, after researchers found a previously unknown genetic pathway linked to anaphylaxis.
news
Scientists develop 3D-printed dermis for faster burn recovery
Researchers have developed a 3D-printed ‘skin in a syringe’, using a patient’s own cells to create functional dermis that could change the way we treat severe burns.
news
Evenamide targets multiple symptoms in schizophrenia models
New preclinical research suggests that evenamide – a glutamate modulator – targets hippocampal hyperexcitability, potentially addressing positive, negative and cognitive symptoms of schizophrenia.
news
ecDNA discovery targets ‘zombie’ cells in childhood cancers
Researchers have discovered how circular extra-chromosomal DNA drives relapse in childhood cancers and found a way to target dormant “zombie” tumour cells – which could allow for the development of more durable treatments.
